Globus Medical Inc. Class A Common Stock vs Wendys Co — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Wendys Co trades at $6.48 (market cap $1.21B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 8.5× Wendys Co's market cap, and Wendys Co pays a 4.41% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Wendys Co for 78 Days on average.
| GMED | WEN | |
|---|---|---|
Market Cap | $10.25B | $1.21B |
Volume | 1,108,124 | 3,737,069 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $9.33 |
52-Week Low | $58.33 | $6.10 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $9.76B | $4.94B |
Dividend Yield | — | 4.41% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Wendy's stock trades at $6.44, up 2.06% today, but remains near multi-year lows amid ongoing operational challenges. The company shows attractive valuation metrics with a P/E of 9.62 and P/S of 0.55, while maintaining consistent revenue around $2.2B. However, declining net income margins (5.72% in 2025) and a major franchisee bankruptcy highlight significant headwinds. Technical indicators show bearish momentum with the stock trading near key support levels.
While Wendy's valuation appears compelling, the stock faces substantial risks from declining profitability, high debt levels, and competitive pressures. Analyst consensus leans cautious with a $7.58 price target, suggesting limited upside. The recent CEO change and international expansion plans offer potential catalysts, but execution risks remain elevated given the challenging restaurant environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →